Bloomberg Anywhere Remote Login Bloomberg Terminal Demo Request


Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.


Financial Products

Enterprise Products


Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000


Industry Products

Media Services

Follow Us

Bloomberg Customers

Bloomberg News

J&J Won’t Enforce Patents on HIV Medicine in Africa

November 29, 2012

Johnson & Johnson, the world’s biggest maker of consumer health products, will let generic-drug companies make and distribute copies of its HIV medicine Prezista (JNJ:US) in sub-Saharan Africa and poor countries.

J&J, based in New Brunswick, New Jersey, won’t enforce patent claims against drugmakers that copy the pill. Prezista, or darunavir, is an antiretroviral medication that’s used to treat the immune system-destroying virus, in combination with other anti-viral drugs.

Last year, J&J sold $1.21 billion of Prezista, making it the company’s sixth best-selling drug. The agreement says that generics manufacturers can only distribute the medicine for patients living in the African and least-developed countries. About 34.2 million people worldwide are infected with HIV, including 22.9 million in Africa, according to the World Health Organization.

“Intellectual property should not be a barrier to ensuring a sustainable supply of medically acceptable darunavir in the world’s poorest countries,” Paul Stoffels, J&J’s worldwide chairman of pharmaceuticals, said in a statement today.

Prezista is used in patients who’ve already been on and failed other HIV treatments because the virus becomes resistant to them. Today’s statement didn’t identify specific countries subject to the agreement.

To contact the reporter on this story: Drew Armstrong in New York at;

To contact the editor responsible for this story: Reg Gale at

blog comments powered by Disqus